Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
Pharmaphorum
Biogen bags FDA okay for Tecfidera follow-up Vumerity
Some analysts think it is likely to be an also-ran in the market, with EvaluatePharma predicting around $110 million in sales in 2024, although others are more…
Handelsblatt
The stock market is discovering gene therapy
"Technologies such as Crispr are highly valued," says a study by the British analysis company EvaluatePharma, "but they also represent a high risk. Any serious setback…
Look back at pharma news in the week to October 25
Look back at pharma news in the week to October 25
The sell-side expects tucatinib to post 2024 sales of $268 million, according to EvaluatePharma consensus.
Neue Zürcher Zeitung
The polycultis of the knee are in enviable form
According to estimates by market research firm Evaluate Pharma, the annual increase in prescription drug sales between 2019 and 2024 will reach almost 7% worldwide.
The Pharma Letter
Look back at pharma news in the week to October 18
EvaluatePharma consensus predicts 2024 palovarotene sales of $357m; there are currently no forecasts for BLU-782, presumably because of its early stage.
Fianze und Wirtschaft
Highly competitive market for cancer drugs
According to an estimate by data service provider EvaluatePharma, about $ 182 billion will be spent on research and development this year, much of it to fight more than…
Nature Reviews Drug Discovery
FDA new drug approvals in Q3 2019
The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of…
PMLive
SMC approves Yescarta and Keytruda, rejects Perjeta
This latest approval will allow Keytruda to continue on its upwards trajectory – Evaluate Pharma has forecasted that it will be the top-selling drug worldwide in 2024 at…
PMLive
Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
Analysts think that Beovu has the potential to grow quickly to blockbuster sales levels, with...EvaluatePharma pegging it at a more modest $1.3bn in 2024.
The Pharma Letter
Look back at pharma news in the week to October 4
Doptelet could be worth more to the Swedish group, according to EvaluatePharma's NPV analyser.